Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06347705 · ClinicalTrials.gov registry record · Phase 2
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 7
- Study locations
NCT06347705: Recruiting Phase 2 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06347705 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 99 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (84% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06347705, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells. Researchers will look at whether this treatment approach is able to completely get rid of cancer in participants, and they will check for the presence of minimal residual disease (MRD) in participants. MRD is a small number of cancer cells that can be detected in the body after treatment.
Primary Outcome
To determine the proportion of patients in each cohort in whom a pathologic complete response (pCR) or minimal residual disease (pMRD, ≤ 5mm tumor) is observed in the resected primary tumor.
Conditions Studied
Interventions
- BIOLOGICAL 2141-V11 Antibody
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activites) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activites) - Rockville Centre
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2024-03-28 |
| Est. Completion | 2029-03-28 |
| Phase | Phase 2 |
What NCT06347705 shows while recruiting
NCT06347705 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which 2141-V11 Antibody is the first listed.
NCT06347705 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06347705 about?
NCT06347705 is a clinical study titled "A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer". The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells. Researchers will look at whether this treatment approach is able to co...
What is the current status of trial NCT06347705?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2024-03-28. Estimated completion is 2029-03-28.
What conditions does trial NCT06347705 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06347705?
The interventions under investigation include: 2141-V11 Antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT06347705?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06347705 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06347705's enrollment target sits among peer trials
99 348th of 735 higher than 388 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI